Especially, in area where the LMiPD of TTFields is low, recurrence tumor might exhibit MRI and pathologic findings of lower grade glioma in spite of typical molecular features of glioblastoma, IDH-wildtype due to modification of continuous TTFields treatment. The gene discussed is IDH2; the disease is central nervous system cancer.